Roland Seiler

Roland Seiler

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in European Urology
Verified
Journal Article
Open access
AKAurélie Kamoun
Aurélie Kamoun
ARAurélien de Reyniès
Aurélien de Reyniès
YAYves Allory
Yves Allory
GSGottfrid Sjödahl
Gottfrid Sjödahl
ARA. Gordon Robertson
A. Gordon Robertson
JWJohn Weinstein
John Weinstein
Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting.

1 October 2017 in European Urology
Verified
Journal Article
Closed access
RSRoland Seiler
Roland Seiler
HAHussam Al Deen Ashab
Hussam Al Deen Ashab
NENicholas Erho
Nicholas Erho
BRBas W.G. van Rhijn
Bas W.G. van Rhijn
BWBrian Winters
Brian Winters
Peter Colin BlackPeter Colin Black
Peter Colin Black

1 December 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
SZShuang G. Zhao
Shuang G. Zhao
SCS. Laura Chang
S. Laura Chang
NENicholas Erho
Nicholas Erho
MYMenggang Yu
Menggang Yu
JLJonathan Lehrer
Jonathan Lehrer
FFFelix Y. Feng
Felix Y. Feng
The lineage of prostate cancer is unknown. Prostate cancer was first thought to derive from glandular luminal cells; however, there is mounting evidence that basal cells may also play a role in prostate carcinogenesis.1 Mouse models have demonstrated that both luminal and basal cells include self-sustaining lineages that can give rise to prostate cancer.2 Recent work has sought to characterize luminal3 and basal4 cells that display characteristics similar to those of stem cells. However, this is an area of active research, and the similarities and differences of luminal and basal prostate cancer remain unresolved.5,6

1 August 2011 in European Urology
Verified
Journal Article
Closed access
AFAchim Fleischmann
Achim Fleischmann
DRDiana Rotzer
Diana Rotzer
RSRoland Seiler
Roland Seiler
USUrs E. Studer
Urs E. Studer
GTGeorge N. Thalmann
George N. Thalmann

24 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKManav Korpal
Manav Korpal
XPXiaoling Puyang
Xiaoling Puyang
ZWZhenhua Jeremy Wu
Zhenhua Jeremy Wu
RSRoland Seiler
Roland Seiler
CFCraig Furman
Craig Furman
PZPing Zhu
Ping Zhu
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority of patients fail to respond, suggesting existence of complementary immune evasion mechanisms. Here, we report that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion in MIBC. Recurrent mutations in RXRα at serine 427 (S427F/Y), through conformational activation of the PPARγ/RXRα heterodimer, and focal amplification/overexpression of PPARγ converge to modulate PPARγ/RXRα-dependent transcription programs. Immune cell-infiltration is controlled by activated PPARγ/RXRα that inhibits expression/secretion of inflammatory cytokines. Clinical data sets and an in vivo tumor model indicate that PPARγHigh/RXRαS427F/Y impairs CD8+ T-cell infiltration and confers partial resistance to immunotherapies. Knockdown of PPARγ or RXRα and pharmacological inhibition of PPARγ significantly increase cytokine expression suggesting therapeutic approaches to reviving immunosurveillance and sensitivity to immunotherapies. Our study reveals a class of tumor cell-intrinsic “immuno-oncogenes” that modulate the immune microenvironment of cancer.

1 July 2019 in European Urology
Verified
Journal Article
Closed access
JEJason A. Efstathiou
Jason A. Efstathiou
KMKent W. Mouw
Kent W. Mouw
EGEwan A. Gibb
Ewan A. Gibb
YLYang Liu
Yang Liu
CWChin-Lee Wu
Chin-Lee Wu
DMDavid T. Miyamoto
David T. Miyamoto